The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Nipocalimab shows pharmacodynamic activity in warm autoimmune hemolytic anemia
Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, discusses pharmacodynamic findings for nipocalimab in warm autoimmune hemolytic anemia (wAIHA). He explains how FcRn inhibition rapidly reduced total and pathogenic IgG levels, with these changes correlating with improvements in hemoglobin and markers of hemolysis. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
